Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China · Delayed Price · Currency is CNY 48.87
-4.21 (-7.93%)
Jun 1, 2026, 3:00 PM CST
SHA:688513 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,350 | 1,329 | 1,348 | 1,116 | 1,170 | 1,023 |
Other Revenue | 2.3 | 2.3 | 1.84 | 1.42 | 0.63 | 0.07 |
| 1,352 | 1,331 | 1,350 | 1,117 | 1,171 | 1,023 | |
Revenue Growth (YoY) | 0.87% | -1.36% | 20.82% | -4.56% | 14.43% | 10.96% |
Cost of Revenue | 346.12 | 336.21 | 345.23 | 226.94 | 199.11 | 146.32 |
Gross Profit | 1,006 | 995.18 | 1,005 | 890.18 | 971.4 | 876.62 |
Selling, General & Admin | 529.28 | 517.78 | 552.93 | 483.43 | 564.44 | 528.06 |
Research & Development | 274.3 | 262.74 | 262.77 | 237.45 | 229.99 | 199.59 |
Other Operating Expenses | 19.99 | 15.94 | 17.37 | 17.46 | 18.15 | 15.75 |
Operating Expenses | 823.32 | 796.24 | 836.11 | 737.98 | 814 | 741.14 |
Operating Income | 182.57 | 198.94 | 168.42 | 152.2 | 157.4 | 135.47 |
Interest Expense | -2.37 | -2.51 | -3.68 | -3.42 | -2.61 | -0.36 |
Interest & Investment Income | 50.44 | 52.11 | 27.38 | 25.61 | 20.69 | 32.83 |
Currency Exchange Gain (Loss) | -0.42 | -0.42 | 0.16 | 0 | 0.03 | 0.02 |
Other Non Operating Income (Expenses) | -0.5 | -0.1 | 0.28 | -0.1 | -0.11 | -0.19 |
EBT Excluding Unusual Items | 229.71 | 248.01 | 192.56 | 174.29 | 175.41 | 167.77 |
Gain (Loss) on Sale of Investments | 19.56 | 17.13 | 14.92 | 14.57 | 19.99 | 13.69 |
Gain (Loss) on Sale of Assets | -0.16 | -0.18 | -0.11 | 0.03 | 0.19 | -0.1 |
Other Unusual Items | 34.73 | 34.69 | 45.22 | 52.76 | 66.4 | 65.56 |
Pretax Income | 284.64 | 299.65 | 252.59 | 241.64 | 261.99 | 246.92 |
Income Tax Expense | 28.37 | 26.08 | 14.35 | 15.07 | 15.47 | 14.49 |
Earnings From Continuing Operations | 256.27 | 273.57 | 238.23 | 226.57 | 246.52 | 232.43 |
Minority Interest in Earnings | 18.03 | 10.49 | - | - | - | - |
Net Income | 274.3 | 284.06 | 238.23 | 226.57 | 246.52 | 232.43 |
Net Income to Common | 274.3 | 284.06 | 238.23 | 226.57 | 246.52 | 232.43 |
Net Income Growth | 22.56% | 19.23% | 5.15% | -8.09% | 6.06% | 30.46% |
Shares Outstanding (Basic) | 174 | 174 | 175 | 177 | 177 | 176 |
Shares Outstanding (Diluted) | 174 | 174 | 175 | 177 | 177 | 176 |
Shares Change (YoY) | -1.46% | -0.52% | -1.04% | 0.14% | 0.37% | 19.70% |
EPS (Basic) | 1.58 | 1.63 | 1.36 | 1.28 | 1.39 | 1.32 |
EPS (Diluted) | 1.58 | 1.63 | 1.36 | 1.28 | 1.39 | 1.32 |
EPS Growth | 24.38% | 19.85% | 6.25% | -8.22% | 5.68% | 8.98% |
Free Cash Flow | 220.46 | 178.66 | 145.82 | 99.99 | -187.38 | -122.59 |
Free Cash Flow Per Share | 1.27 | 1.02 | 0.83 | 0.56 | -1.06 | -0.70 |
Dividend Per Share | 0.490 | 0.490 | 0.430 | 0.395 | 0.381 | 0.531 |
Dividend Growth | 13.95% | 13.95% | 8.97% | 3.57% | -28.19% | 159.97% |
Gross Margin | 74.40% | 74.75% | 74.42% | 79.68% | 82.99% | 85.70% |
Operating Margin | 13.50% | 14.94% | 12.48% | 13.62% | 13.45% | 13.24% |
Profit Margin | 20.29% | 21.34% | 17.65% | 20.28% | 21.06% | 22.72% |
Free Cash Flow Margin | 16.31% | 13.42% | 10.80% | 8.95% | -16.01% | -11.98% |
EBITDA | 275.6 | 289.92 | 251.25 | 225.43 | 215.75 | 168.08 |
EBITDA Margin | 20.38% | 21.78% | 18.62% | 20.18% | 18.43% | 16.43% |
D&A For EBITDA | 93.02 | 90.99 | 82.84 | 73.23 | 58.35 | 32.6 |
EBIT | 182.57 | 198.94 | 168.42 | 152.2 | 157.4 | 135.47 |
EBIT Margin | 13.50% | 14.94% | 12.48% | 13.62% | 13.45% | 13.24% |
Effective Tax Rate | 9.97% | 8.70% | 5.68% | 6.24% | 5.90% | 5.87% |
Revenue as Reported | 1,352 | 1,331 | 1,350 | 1,117 | 1,171 | 1,023 |
Advertising Expenses | - | - | - | - | 403 | 393.56 |